Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yinaokang capsule is a Traditional Chinese Medicine (TCM) herbal formulation developed by the **GuangDong Provincial Hospital of Chinese Medicine**. It is specifically designed for the treatment of **post-stroke cognitive impairment without dementia (PSCI-ND)**. The formulation is typically administered orally as an adjunct to standard Western medical care. While the precise molecular mechanisms are multi-targeted, the therapy is intended to improve cognitive function, potentially through neuroprotective effects, modulation of cerebral blood flow, and anti-inflammatory pathways. It has been evaluated in clinical trials in China to assess its efficacy, safety, and underlying biochemical mechanisms in adult stroke survivors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yinaokang capsule.